IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)

G. F. Bottazzo, E. Bosi, C. A. Cull, E. Bonifacio, M. Locatelli, P. Zimmet, I. R. MacKay, R. R. Holman

Research output: Contribution to journal › Article › peer-review

Abstract

Aims/hypothesis: Established autoimmune markers of type 1 diabetes, including islet cell autoantibodies (ICA) and autoantibodies to glutamic acid decarboxylase (GADA) have been used to screen people presenting with type 2 diabetes for latent autoimmune diabetes in adults. We have examined the prevalence of autoantibodies to protein tyrosine phosphatase isoforms IA-2 (IA-2A) and IA-2β/phogrin (IA-2βA) in a cohort of adult UKPDS patients thought to have type 2 diabetes, and investigated the possible role of these autoantibodies in predicting requirement for insulin therapy. Methods: IA-2A and IA-2βA were measured by a validated radioimmunoassay with human recombinant autoantigens in 4,169 white Caucasian patients aged 25-65 years and newly diagnosed with type 2 diabetes. The clinical requirement for insulin therapy within 6 years was examined in 2,556 patients not randomised to insulin. Results: IA-2A and IA-2βA were present in 2.2 and 1.4%, respectively, of these patients. IA-2A were more prevalent in younger patients (p for trend

Original languageEnglish
Pages (from-to)703-708
Number of pages6
JournalDiabetologia
Volume48
Issue number4
DOIs
Publication statusPublished - Apr 2005

Keywords

  • GADA
  • IA2A
  • ICA
  • Insulin requirement
  • Islet cell autoantibodies
  • Type 2 diabetes
  • UKPDS

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Access to Document

Fingerprint Dive into the research topics of 'IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71)'. Together they form a unique fingerprint.

Cite this